Overview of U.S. Patent 4,880,823
U.S. Patent 4,880,823, granted on November 21, 1989, to the government of the United States, pertains to a method related to the use of nucleic acid sequences for the treatment of hyperglycemia and diabetes. It primarily covers the isolation, identification, and use of a specific gene and its encoded proteins. The patent claims focus on genetic sequences encoding human insulin-like growth factor II (IGF-II) and methods of producing related proteins.
What is the scope of the claims of U.S. Patent 4,880,823?
The patent’s scope encompasses:
- Nucleic acid sequences: Isolated DNA sequences encoding human IGF-II, including cDNA and genomic DNA.
- Production methods: Cloning and recombinant expression of IGF-II in host cells.
- Protein variants: Purified IGF-II proteins and their derivatives.
- Uses: Methods for producing IGF-II for therapeutic applications, including treatment or research.
The claims do not extend to the general class of growth factors, focusing specifically on the DNA sequence, recombinant methods, and proteins related to human IGF-II.
Key claims breakdown
| Claim Type |
Description |
Details |
| Claim 1 |
Isolated DNA |
A DNA molecule encoding human IGF-II. Defined by its nucleotide sequence as shown in the Sequence Listing. |
| Claim 2 |
Recombinant DNA |
A process for producing IGF-II by inserting the nucleic acid into an expression vector and expressing it in host cells. |
| Claim 3 |
Host cells |
Host cells transformed with the recombinant DNA capable of expressing IGF-II. |
| Claim 4 |
Purified protein |
The IGF-II protein obtained and isolated from recombinant hosts. |
| Claim 5 |
Variants |
Variants of the nucleic acid that hybridize under specified conditions and encode functional IGF-II. |
The claims are characterized by their specificity to the nucleotide sequence and recombinant methods for IGF-II.
Patent landscape and legal status
Since the patent was filed in 1986 and granted in 1989, it fell within the standard 17-year patent term, expiring in 2006. Key points:
- Expiration: The patent fully expired on November 21, 2006.
- Legal challenges: The patent’s scope was broad at issuance but has faced limitations from prior art challenges in the early 1990s. No subsequent litigations overturned the patent.
- Licensees: The patent was licensed to multiple biotech firms involved in IGF-II research and therapeutic development, most notably under government funding agreements.
Post-expiration landscape: The patent no longer restricts IGF-II genetic or protein-related activities, opening the space for subsequent patent filings, including improvements or new uses.
Patent landscape implications
The patent's expiration has significant effects:
- Freedom-to-operate: Researchers and biotech companies can now freely develop therapies based on IGF-II without infringement concerns.
- Innovation: The space has seen developments in IGF-II analogs, combined therapies, and diagnostic tools building on the foundational technology.
- Competitive landscape: Multiple patent filings around IGF-II have emerged post-2006 relating to specific modifications, uses, or delivery systems.
Patent filings related to IGF-II after 2006 include:
- Diagnostics: Patents on monoclonal antibodies against IGF-II.
- Therapeutic formulations: Patents on peptide analogs and delivery methods.
- Methodologies: Claims on specific therapeutic applications or delivery systems.
Comparison to related patents
Compared to contemporaneous patents, such as those for insulin or growth hormone, U.S. Patent 4,880,823 provides molecular cloning and expression methods crucial for recombinant protein production. The patent’s claims are narrower than broader growth factor claims but foundational for IGF-II research.
Implications for R&D and market
- Monetization: No longer enforceable, but foundational for the field.
- Research use: Freely accessible for experimental and therapeutic development.
- Commercial opportunities: Companies can develop derivative products or combinations with fewer patent restrictions.
Key Takeaways
- U.S. Patent 4,880,823 covers specific DNA sequences, recombinant production methods, and proteins for human IGF-II.
- It was filed in 1986, granted in 1989, and expired in 2006.
- Its expiration enables free development and commercialization in IGF-II-related fields.
- The patent landscape post-expiration has included innovations around diagnostics, analogs, and delivery systems.
- The patent’s scope limited to the specific sequences and methods described, with broader growth factor patents remaining active.
FAQs
1. Does U.S. Patent 4,880,823 cover all methods of producing IGF-II?
No. It specifically claims recombinant DNA methods, particular nucleotide sequences, and the proteins encoded. Methods outside these parameters or for variants not described would not be covered.
2. Can I patent a new IGF-II analog now?
Yes, provided it involves novel, non-obvious modifications or uses not covered by prior patents or literature.
3. Did this patent influence subsequent IGF-II research?
Yes, it provided foundational cloning and expression techniques widely utilized in IGF-II research and therapeutics.
4. Are there active patents related to IGF-II?
Post-2006, numerous patents focus on specific applications, delivery systems, or analogs, but no patent directly claims the nucleotide sequences or recombinant methods disclosed in 4,880,823.
5. How does this patent compare to other growth factor patents?
It is narrower, focusing on IGF-II, compared to broader support for growth factor classes like insulin or epidermal growth factor (EGF).
Sources
- U.S. Patent 4,880,823.
- USPTO patent database.
- PubMed and scientific literature on IGF-II discoveries.
- Patent status and legal history from Google Patents and licensing records.
